Why analysts say Hub24, New Hope, and Xero shares are buys

If you are looking for some new portfolio additions, then it could be worth checking out the ASX shares named below.

They have been named by analysts as buys this week, courtesy of The Bull. Here's what they are recommending:

Hub24 Ltd (ASX: HUB)

The team at Catapult Wealth has named investment platform provider Hub24 as a buy this week.

It has been impressed with its performance in FY 2026 and believes its outlook is positive given its increasing funds under administration. It said:

HUB24 operates an investment and superannuation platform. The company posted strong growth in the second quarter of fiscal year 2026. Record quarterly platform net inflows of $5.6 billion were up 2 per cent on the prior corresponding period and significantly higher than consensus forecasts. Excluding large migrations, platform net inflows were up 42 per cent.

Quarterly and annual net inflows lifted the company's market share in platform administration to 9.3 per cent as at September 30, 2025, up from 7.9 per cent in the prior corresponding period. Attracting increasing funds paints a bright outlook for profits moving forward.

New Hope Corporation Ltd (ASX: NHC)

Over at Baker Young, its analysts think coal miner New Hope could be a buy this week.

It highlights that Origin Energy Ltd (ASX: ORG) is extending the life of its coal fired power station, which is good news for coal demand.

Baker Young also notes that its balance sheet is strong and is well-placed to develop the New Acland operation. It said:

The extension of Origin Energy's Eraring coal fired power station is a reminder that demand for thermal coal is likely to remain robust for longer than many investors believe. New Hope group saleable coal production of 2.7 million tonnes for the quarter ending October 31, 2025 was up 7.1 per cent on the previous quarter. Underlying EBITDA of $107.9 million for the quarter was up 15.5 per cent on the prior quarter.

New Hope has a strong balance sheet, and we feel the market is undervaluing NHC's growth potential through the New Acland stage 3 development. Recently trading on a modest forecast earnings multiple in fiscal year 2026 and an attractive fully franked dividend yield, the stock screens as attractive.

Xero Ltd (ASX: XRO)

Finally, analysts at Morgans are bullish on cloud accounting platform provider and have named it as a buy.

The broker thinks that recent share price weakness has created a buying opportunity for investors. It explains:

Xero is a global accounting software provider. It offers an attractive medium term growth opportunity as subscriber momentum improves and operating leverage begins to flow through the business model. The business continues to expand its footprint across key geographies, with cloud accounting penetration still well below potential, providing a long runway for adoption.

Recent cost discipline has strengthened margins. Despite a softer macroeconomic backdrop, resilient revenue growth is supported by price increases and a broader ecosystem of adjacent services. We view the current share price as an attractive entry point for long term investors.

The post Why analysts say Hub24, New Hope, and Xero shares are buys appeared first on The Motley Fool Australia.

Motley Fool contributor James Mickleboro has positions in Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Hub24 and Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended Hub24. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026